Yeah, thats valid. And I agree EJ isn't the story. But I dont think Macudrop is the story either. I just can't figure out what distinguishes it from the other versions, with the exception of it being an oral application. But the macustrips address the same small market segment that need the vitamins and can't take pills. So yes, people will buy it, and again, i'm glad we have it out there and really glad to hear initial reports are that its going well. But this isn't the behind the scenes story. This isn't pharma. Just another bridge, like our current three products, to support us to get to pharma.
Unfortunately, I personally think pharma applications are a joke at this point, so my pps hopes are only with the gains that we can make from our current products.
News 
Market Data 
Discover 
AI
